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INTRODUCTION
Pseudomonas aeruginosa (PA), an aerobic, nonfermenting Gram-
negative rod bacterium, is one of the most troublesome bacteria 
in hospital-acquired infections. Infections caused by PA can cause 
various diseases, including otitis externa, osteomyelitis, menin-
gitis, endocarditis, pneumonia, urinary tract infection and septi-
cemia (1).
  Although PA is inherently resistant to several antibiotics, it was 
originally sensitive to the anti-pseudomonal beta-lactam class 
antibiotics, such as ceftazidime (CAZ), cefepime (CFP), and car-
bapenem, which were usually used to treat PA infections. More 
recently, however, bacteria, including PA, have acquired resis-
tances to many antibiotics, giving rise to an increasing number 
of multidrug-resistant strains resistant to CFP and imipenem 
(IMP) (2).
  Chronic suppurative otitis media (CSOM) is an inflammatory 
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disorder that causes irreversible changes of the mucosa in the 
middle ear and mastoid cavity. Dysfunction of the Eustachian 
tubes and bacterial infection are the most important pathogenic 
factors for CSOM. Owing to the long period of morbidity of 
CSOM and the repeat occurrences of otorrhea during that peri-
od, patients with this condition are often prescribed empiric an-
tibiotics in outpatient clinics without microbiologic evaulation. 
Bacteria identified in patients with CSOM otorrhea (e.g., Staph-
ylococci and PA) differed from those in patients with acute otitis 
media (e.g., Streptococcus pneumoniae, Moraxella catarrhalis, 
and Haemophilus influenzae). One study found that the bacteri-
um isolated most frequently from CSOM otorrhea was Staphy-
lococci, followed by PA (3). If, however, the Staphylococci iso-
lates were divided to methicillin-resistant (MRSA), methicillin-
sensitive (MSSA), and coagulase-negative (CNS), then PA was 
the most commonly isolated bacterium from CSOM otorrhea 
(3).
  To determine the validity of these findings, we assessed the 
overall rates of isolation of PA and multidrug-resistant PA (MDR-
PA) from otorrhea of CSOM. We also analyzed changes over 
time in the rate of isolation of MDR-PA and in the antibiotic-re-
sistance patterns of PA. 
MATERIALS AND METHODS
The study population consisted of 1,598 CSOM patients (799 
males, 834 females) who visited the Department of Otolaryn-
gology at the outpatient clinics of 6 general hospitals throughout 
Korea between January 2001 and December 2008. Mean pa-
tient age was 45.6 (±17.4) years (range, 1 to 91 years). A total 
of 1,633 otorrhea samples was collected, with PA isolated from 
398 samples from 398 patients (186 males, 212 females). The 
mean age of these 398 patients was 45.5 (±17.3) years (range, 
2 to 91 years). Of these 398 patients, 286 (71.9%) had non-
cholesteatomatous CSOM, 106 (26.6%) had cholesteatomatous 
CSOM, and 6 (1.5%) were unclassified. 
  At the first visit, the external auditory canal of each patient 
was cleaned well, and the aural discharge was collected with 
cotton swabs while using a sterilized otoscope to prevent con-
tact with the external auditory canal. All clinical samples were 
added to Stuart transport medium and transported to a microbi-
ology test laboratory within 1 hour of collection. The, samples 
were inoculated into blood agar medium and cultured for 24 
hours at 35°C. Bacteria were identified by Gram staining and 
biochemical tests. 
  All antibiotic-sensitivity tests followed the guidelines of the 
Clinical and Laboratory Standards Institute. PA were tested for 
sensitivity to amikacin (AMK), gentamicin (GM), tobramycin 
(TOB), CAZ, CFP, piperacillin (PIP), PIP/tazobactam (PITA), 
IMP, ciprofloxacin (CIP), and levofloxacin (LFX) by the disc dif-
fusion method using Mueller-Hinton agar medium (Difco, Cock-
eysville, MD, USA) (4).
  There is no clear and official definition of MDR. Generally, 
however, resistance to more than three core antibiotics (i.e., 
AMK and/or GM, CAZ, CIP, IMP, and PIP-ticarcillin) is classi-
fied as MDR (5). In this study, we defined MDR as resistance to 
at least three of the five core antibiotics (AMK, CAZ, PIP, CIP, 
and IMP). 
  In general, antibiotics of the same class act via the same anti-
bacterial mechanism. However, differences in absorption, distri-
bution, metabolism and excretion from the human body caused 
by molecular differences result in pharmacokinetic differences 
and hence different anti-bacterial potencies. Thus, although AMK, 
GM, and TOB all belong to the same class of antibiotics (amino-
glycosides), AMK is usually the most potent of these three anti-
biotics. Clinically, bacteria susceptible to AMK are not always 
susceptible to GM and TOB.
  Another approach to enhancing anti-bacterial potency is to 
add an inhibitory material (a hydrolase) to an antibiotic. For ex-
ample, PITA is a complex, anti-pseudomonal penicillin (PIP) 
containing a penicillinase inhibitor (tazobactam). However, al-
teration of the structure of the bacterial penicillin-binding site 
can make bacteria resistant not only to PIP but also to PITA. In 
practice, the definition of MDR as resistance to five core antibi-
otics may have clinical limitations. In this study, we therefore 
additionally categorized 10 antibiotics into 5 classes-aminogly-
cosides (AMK, GM, TOB), cephalosporins (CAZ, CFP), anti-
pseudomonal penicillins (PIP, PITA), carbapenem (IMP), and 
quinolones (CIP, LFX)-and defined modified-MDR (mMDR) as 
resistance to at least 3 of these 6 classes. 
  In designations of mMDR, resistance to at least 1 individual 
antibiotic in each class was defined as resistance to that entire 
class. 
  SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA) was used for 
statistical analysis. The annual changes in overall resistance of 
PA and MDR-PA isolation rate were analyzed by the linear by 
linear association method. Statistical significance was defined as 
a P-value <0.05.
RESULTS
Of the 398 isolated strains tested for sensitivity to 12 antibiotics, 
395 showed definitive results, with a total of 3,241 combinations 
tested. Of these, 183 (46.3%) strains showed susceptibility to all 
of 10 antibiotics tested. Sixty-two (15.6%) strains were resistant 
to 3 antibiotics and 38 (9.6%) strains were resistant to 1 antibi-
otic (Fig. 1). If tested 10 antibiotics were classified into 5 classes, 
majority of PA strain was susceptible to whole 5 classes antibi-
otics 183, 46.3%), following resistant to 2 classes (74, 18.7%), 3 
classes (51, 12.9%), and 1 class (48, 12.1%) (Fig. 2). Between 
2001 and 2008, the rate of antibiotic resistance increased signifi-
cantly over time, whereas the rate of susceptibility decreased Lee SK et al.: Antimicrobial Resistance of Multidrug Resistant Pseudomonas Aeruginosa    19
significantly (linear by linear association, P=0.003) (Table 1). 
The rate of resistance to quinolones (55.7%) was highest, fol-
lowed by rates of resistance to aminoglycosides (50.0%), anti-
pseudomonal penicillins (26.1%) and cephalosporins (13.3%) 
(Table 1).
  When the strains were classified as susceptible to all antibiot-
ics and resistant to ≥1 antibiotic, we observed a significant de-
crease in the former over time (Table 2). The rates of isolation of 
MDR strains, defined as strains resistant to at least three of five 
antibiotics (AMK, CAZ, PIP, IMP, and CIP), and mMDR strains 
(i.e., strains resistant to more than three antibiotic-classes), 
showed no trends over time (Table 2).
Fig. 1. Frequency of isolated Pseudomonas aeruginosa strains from 
otorrhea, as determined by antibiotic-susceptibility test. 
0 1 2 3 4 5 6 7 8
200
150
100
50
0
N
o
.
 
o
f
 
P
s
e
u
d
o
m
o
n
a
s
 
a
e
r
u
g
i
n
o
s
a
 
s
t
r
a
i
n
s
No. of antibiotics to which Pseudomonas aeruginosa 
showed resistance
183
38
11
62
38
27 22
12
2
Fig. 2. Frequency of isolated Pseudomonas aeruginosa strains from 
otorrhea, as determined by resistance to six classes of antibiotics.
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Table 1. Annual isolation rate of Pseudomonas aeruginosa strains susceptible and resistant to each antibiotic class
Antibiotic 
class  
Year 2001 2002 2003 2004 2005 2006 2007 2008 Total
Test for 
trends
Aminoglycosides Susceptible 8 28 46 20 30 29 14 9 184 0.006*
(66.6) (66.6) (55.4) (37.7) (50.8) (47.5) (45.1) (33.3) (50.0)
Resistant 4 14 37 33 29 32 17 18 184
(33.3) (33.3) (44.5) (62.2) (49.1) (52.4) (54.8) (66.6) (50.0)
Cephalosporins Susceptible 12 41 69 33 54 46 30 26 311 0.267
(100.0) (97.6) (78.4) (71.7) (94.7) (80.7) (100.0) (96.2) (86.6)
Resistant 0 1 19 13 3 11 0 1 48
(0.0) (2.3) (21.5) (28.2) (5.2) (19.2) (0.0) (3.7) (13.3)
Anti-pseudomonal  Susceptible 10 22 62 31 51 44 20 22 262 0.938
penicillins (76.9) (88.0) (71.2) (59.6) (86.4) (69.8) (66.6) (84.6) (73.8)
Resistant 3 3 25 21 8 19 10 4 93
(23.1) (12.0) (28.7) (40.3) (13.5) (30.1) (33.3) (15.3) (26.1)
Imipenem Susceptible 3 41 66 46 53 62 28 25 324 0.452
(100.0) (97.6) (97.0) (97.8) (100.0) (100.0) (90.3) (96.1) (97.5)
Resistant 0 1 2 1 0 0 3 1 8
(0.0) (2.3) (2.9) (2.1) (0.0) (0.0) (9.6) (3.8) (2.4)
Quinolones Susceptible 11 13 15 18 33 27 11 8 136 0.006*
(91.6) (81.2) (33.3) (33.9) (55.0) (42.8) (35.4) (29.6) (44.2)
Resistant 1 3 30 35 27 36 20 19 171
(8.3) (18.7) (66.6) (66.0) (45.0) (57.1) (64.5) (70.3) (55.7)
Total Susceptible 44 145 258 148 221 208 103 90 1,217 0.003*
(84.6) (86.8) (69.5) (59.0) (76.7) (68.0) (67.3) (67.7) (70.7)
Resistant 8 22 113 103 67 98 50 43 504
(15.4) (13.2) (30.5) (41.0) (23.3) (32.0) (32.7) (32.3) (29.3)
*P<0.05.20    Clinical and Experimental Otorhinolaryngology   Vol. 5, No. 1: 17-22, March 2012
  Strains resistant to one class of antibiotics tend to be more re-
sistant to aminoglycosides or quinolones than to other classes. 
In contrast, resistance to cephalosporins or anti-pseudomonal 
penicillins was less frequent in strains resistant to one class of 
antibiotics but was high in multi-antibiotic-class resistant strains 
(Table 3). We found that resistance to aminoglycosides and qui-
nolones significantly increased over time, whereas resistance to 
the other classes of antibiotics showed no trend (Table 3).
DISCUSSION
PA can colonize various sites of the human body, including the 
sputum, cornea, nasal mucosa and wet skin, causing a range of 
diseases from minor skin infections to fulminant septicemia (6). 
Some β-lactam antibiotics (e.g., CAZ, CFP, IMP, and meropen-
em) that show strong anti-pseudomonal activity have been used, 
alone or in combination with aminoglycosides/quinolones, to 
treat PA infections (7, 8). The rate of isolation of PA strains resis-
tant to CAZ, CFP, and IMP has increased recently, making it 
more difficult to select adequate antibiotics. PA can acquire an-
tibiotic resistance through horizontal and vertical transmission 
(5, 8) and transmission of resistance to several antibiotics (9) can 
develop into MDR, making treatment more difficult. 
  Resistance to aminoglycoside can be acquired by several 
mechanisms including enzyme modification (major), active ef-
flux, low outer membrane permeability, and rarely by target 
modification. Aminoglycoside modifying enzymes (AMEs) can 
attach a phosphate, adenylyl or acetyl radical to the antibiotic 
molecule, and thus they can decrease the binding affinity of the 
Table 2. Annual isolation rate of multidrug-resistant Pseudomonas aeruginosa strains, classified by sensitivity to five core antibiotics and five 
antibiotics-classes
 
Year
PA strain
2001 2002 2003 2004 2005 2006 2007 2008 Total
Test for 
trend
Susceptible to all  
antibiotics
9 31 60 19 29 20 9 6 183 0.000*
(69.20) (67.40) (59.40) (35.20) (48.30) (31.70) (29.00) (22.20) (46.30)
Resistant to more 
than 1 antibiotics
4 15 41 35 31 43 22 21 212
(30.80) (32.60) (40.60) (64.80) (51.70) (68.30) (71.00) (77.80) (53.70)
Total 13 46 101 54 60 63 31 27 395
(100.00) (100.00) (100.00) (100.00) (100.00) (100.00) (100.00) (100.00) (100.00)
Non-MDR strain 13 43 86 50 57 58 22 23 352 0.116
(100.00) (93.50) (85.10) (92.60) (95.00) (92.10) (71.00) (85.20) (89.10)
MDR strain 0 3 15 4 3 5 9 4 43
(0.00) (6.50) (14.90) (7.40) (5.00) (7.90) (29.00) (14.80) (10.90)
Total 13 46 101 54 60 63 31 27 395
(100.00) (100.00) (100.00) (100.00) (100.00) (100.00) (100.00) (100.00) (100.00)
Non-mMDR strain 13 43 75 30 53 49 21 22 306 0.242
(100.00) (93.50) (74.30) (55.60) (88.30) (77.80) (67.70) (81.50) (77.50)
mMDR strain 0 3 26 24 7 14 10 5 89
(0.00) (6.50) (25.70) (44.40) (11.70) (22.20) (32.30) (18.50) (22.50)
Total 13 46 101 54 60 63 31 27 395
(100.00) (100.00) (100.00) (100.00) (100.00) (100.00) (100.00) (100.00) (100.00)
PA, Pseudomonas aeruginosa; MDR, multidrug-resistant; mMDR, modified multidrug-resistant (determined by number of resistance to 5 antibiotics-classes).
*P<0.05.
Table 3. Difference of isolation rate of resistant Pseudomonas aeruginosa according to number of resistance to antibiotics-classes
PA strain  Number 0 1 2 3 4 5 Total
Aminoglycosides-resistant strain 0/161 26/47 70/74 49/51 38/38 1/1 184/372
(0.0) (55.3) (94.6) (96.1) (100.0) (100.0) (49.5)
Cephalosporins-resistant strain 0/171 1/45 3/74 9/50 34/37 1/1 48/379
(0.0) (2.2) (4.1) (18.0) (91.9) (100.0) (12.7)
Anti-pseudomonal penicillins-resistant strain 0/164 4/31 7/74 44/50 37/38 1/1 93/358
(0.0) (12.9) (9.5) (88.0) (97.4) (100.0) (26.0)
Carbapenems-resistant strain 0/137 0/46 1/66 2/48 4/37 1/1 8/335
(0.0) (0.0) (1.5) (4.2) (10.8) (100.0) (2.4)
Quinolones-resistant strain 0/114 17/30 67/74 48/51 38/38 1/1 171/308
(0.0) (56.7) (90.5) (94.1) (100.0) (100.0) (55.5)
Values are presented as number/total number (%).Lee SK et al.: Antimicrobial Resistance of Multidrug Resistant Pseudomonas Aeruginosa    21
modified antibiotics to the target in the bacterial cell (30s ribo-
somal unit) (10). Other mechanisms of aminoglycosides can be 
attributed to a reduced uptake due to the diminished outer 
membrane permeability (11) and active aminoglycoside efflux 
due to MexXY proteins operating simultaneously with OprM, as 
well as with some other outer membrane proteins (12). Methyl-
ation of 16S rRNA by a newly recognized group of 16S rRNA 
methylases is a new mechanism of resistance against aminogly-
coside (13).
  Two major mechanisms may lead to quinolones resistance to 
PA. Modification of the primary target (DNA gyrase, also known 
as topoisomerase II) and secondary target (topoisomerase IV) 
occurs by point mutations in gyrA/gyrB and parC/pare genes 
respectively (14). Four efflux systems identified in PA (MexAB-
OprM, MexCD-OprJ, MexEF-OprN, and MexXY-OprM) also of-
fer resistance not only to quinolones but also to tetracycline, 
chloramphenicol, erythromycin, ethidium bromide and acrifla-
vine (15).
  Another important mechanism in acquired bacterial resis-
tance to antibiotics is the production of extended-spectrum 
β-lactamase (ESBL). Most ESBL-producing bacteria show a high 
degree of resistance to third-generation cephalosporins, includ-
ing CAZ and CFP. To date, three classes of enzymes have been 
described, penicillinase-derivatives (class A), metallo-β-lactamases 
(class B) and oxacillinases (class D). Class A enzymes are encod-
ed on plasmids and may be horizontally transmitted from other 
enteric Gram-negative bacteria (16, 17). PA strains expressing 
class A enzymes develop resistance to ureidopenicillins, CAZ, 
cefpirome, CFP and susceptibility to carboxy- or ureidopenicil-
lin/inhibitor combinations. The class B enzymes hydrolyze IMP 
and meropenem (18), whereas the Class D enzymes have strong 
activity against oxacillin and cloxacillin. All of these enzymes, 
except for OXA-18, are weakly inhibited by clavulanic acid.
  The Korean National Survey of Antimicrobial Resistance has 
reported that 21%, 22%, and 22% of PA strains were resistant 
to CAZ, CFP, and IMP, respectively (19). Similar results were 
seen in a report from 12 tertiary hospitals in Korea, in which 
21%, 22%, and 26% of PA strains were resistant to CAZ, CFP, 
and IMP, respectively (20). We found that 3.8%, 20.4%, and 
2.4% of the PA strains isolated from patients with CSOM otor-
rhea were resistant to CAZ, CFP, and IMP, respectively. Differ-
ences between our results and those of previous studies may be 
due to differences in treatment modality and the frequency of 
antibiotic use between CSOM patients and those with other dis-
eases. 
  We found that the rate of PA resistance to the 10 antibiotics 
tested increased significantly over time, whereas the rate of iso-
lation of strains susceptible to all antibiotics decreased signifi-
cantly. In contrast, the rate of isolation of MDR and mMDR 
strains showed no tendency to increase. Similar results were ob-
served in the rate of isolation of MRSA from otorrhea (3). This 
lack of increase may be associated with growing concerns about 
the development of antibiotic-resistant bacterial strains in hospi-
tals and healthcare centers, prompting more careful infection 
control.
  The non-MDR strains (i.e., those resistant to less than three 
antibiotics) showed greater resistance to aminoglycosides and 
quinolones than to other antibiotics. Resistance to cephalospo-
rins and penicillins was particularly low in non-MDR strains, but 
their rate of isolation increased as the number of drugs to which 
the strain was resistant increased. Resistance to aminoglycosides 
and quinolones tended to increase over time, whereas resistance 
to other antibiotics showed no tendency to increase or decrease. 
Because PA is inherently resistant, due to its encoding of chro-
mosomal AmpC β-lactamase, a cytoplasmic efflux pump and 
porin proteins, the strong resistance to aminoglycosides and qui-
nolones of domestic PA strains from patients with otorrhea may 
be reinforced by a genetic trait or the misuse or overuse of these 
medications. These strains showed higher resistance to the qui-
nolones CIP (55.5%) and LFX (35.4%) than to other antibiotics 
(except GM, TOB, SPT). Quinolones are broad-spectrum antibi-
otics used to treat various PA infections. Moreover, the availabil-
ity of an oral formulation has increased its use in otolaryngology 
because most of these patients are treated in outpatient clinics. 
Quinolones may be prescribed empirically, without culture or 
antibiotic susceptibility testing, for patients with CSOM otorrhea, 
which may strengthen resistance to quinolones. This resistance 
may lead to quinolones no longer being the first-line antibiotic 
in the treatment of CSOM.
  CSOM otorrhea is usually treated using oral medications with 
otic drops (mainly fluoroquinolones). The absence of oral formu-
lations of CAZ, CFP, and IMP has severely limited the use of 
these antibiotics in patients with CSOM otorrhea, thus restrict-
ing the ability of these bacteria to develop resistance to these 
antibiotics. IMP is regarded as the final medication for MDR PA 
infection. Strains resistant to CAZ, CFP, and IMP/meropenem 
may be difficult to treat due to the absence of adequate antibi-
otics. This may require treatment with polymyxin (colistin; poly-
myxin E), which is associated with severe nephrotoxicity and 
neurotoxicity, severely limiting its usage. As a drug of last resort, 
however, polymyxin has shown some success. Polymyxin, alone 
or with a β-lactam antibiotic, was successful in the treatment of 
patients with septicemia, pneumonia, and urinary tract infec-
tions (21, 22). In otolaryngology, fluoroquinolones are usually 
prescribed as otic drops even if the isolated strains are resistant 
to quinolones because the concentration of antibiotic in otic 
drops in the middle ear and mastoid cavities is high enough to 
overcome the minimal inhibitory concentrations of resistant 
strains. Moreover, treatment outcomes are quite good. Surgery 
also plays an important role in the treatment of CSOM. Many 
patients can be cured by otic drops and surgery, thus reducing 
the use of last-resort drugs such as IMP. This may explain, at 
least in part, why resistance to IMP in bacteria from CSOM 
otorrhea is lower than in other types of bacterial infection (19, 22    Clinical and Experimental Otorhinolaryngology   Vol. 5, No. 1: 17-22, March 2012
20). 
  The rate of isolation of PA from CSOM otorrhea was 24.4% 
and the total resistance rate was 28.2%. MDR strains classified 
by resistance to five individual antibiotics and mMDR strains 
classified by resistance to six classes of antibiotics showed no 
tendency to increase or decrease over time. However, the resis-
tance rates and patterns of resistance to each antibiotic were 
quite different. Because all analyzed PA strains were obtained 
from clinical samples taken at outpatient clinics of primary care 
centers or tertiary teaching hospitals, these strains likely repre-
sent the general characteristics of PA in CSOM otorrhea in Ko-
rea. Although we assessed the rates of isolation of PA and MDR-
PA from otorrhea, we did not examine the antibiotics actually 
used, the treatment results, or the antibiotic-resistance patterns 
relative to the use of previous antibiotics. Further studies are re-
quired to determine the nature of MDR-PA infections.
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was re-
ported.
REFERENCES
1. Bergogne-Berezin E. Pseudomonas and miscellaneous gram-nega-
tive bacilli. In: Cohen J, Powderly WG, editors. Infectious diseases. 
2nd ed. Philadelphia, PA: Mosby; 2004. p. 2203-26.
2. Song W, Woo HJ, Kim JS, Lee KM. In vitro activity of beta-lactams 
in combination with other antimicrobial agents against resistant 
strains of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2003 
Jan;21(1):8-12.
3. Park DC, Lee SK, Cha CI, Lee SO, Lee MS, Yeo SG. Antimicrobial 
resistance of Staphylococcus from otorrhea in chronic suppurative 
otitis media and comparison with results of all isolated Staphylococ-
ci. Eur J Clin Microbiol Infect Dis. 2008 Jul;27(7):571-7.
4. Wikler MA; Clinical and Laboratory Standards Institute. Perfor-
mance standards for antimicrobial susceptibility testing: sixteenth 
informational supplement. Wayne, PA: Clinical and Laboratory 
Standards Institute; 2006.
5. Livermore DM. Multiple mechanisms of antimicrobial resistance in 
Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis. 2002 
Mar 1;34(5):634-40.
6. Pollack M. Pseudomonas aeruginosa. In: Mandell GL, Bennett JE, 
Dolin R, editors. Mandell, Douglas and Bennett’s principles and 
practice of infectious diseases. 5th ed. Edinburgh, UK: Churchill 
Livingstone; 2000. p. 2310-27.
7. Jones RN, Kirby JT, Beach ML, Biedenbach DJ, Pfaller MA. Geo-
graphic variations in activity of broad-spectrum beta-lactams against 
Pseudomonas aeruginosa: summary of the worldwide SENTRY An-
timicrobial Surveillance Program (1997-2000). Diagn Microbiol In-
fect Dis. 2002 Jul;43(3):239-43.
8. Walsh TR, Toleman MA, Hryniewicz W, Bennett PM, Jones RN. Evo-
lution of an integron carrying blaVIM-2 in Eastern Europe: report 
from the SENTRY Antimicrobial Surveillance Program. J Antimi-
crob Chemother. 2003 Jul;52(1):116-9.
9. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of 
antibiotic-resistant Pseudomonas aeruginosa: comparison of risks 
associated with different antipseudomonal agents. Antimicrob 
Agents Chemother. 1999 Jun;43(6):1379-82.
10. Llano-Sotelo B, Azucena EF Jr, Kotra LP, Mobashery S, Chow CS. 
Aminoglycosides modified by resistance enzymes display dimin-
ished binding to the bacterial ribosomal aminoacyl-tRNA site. 
Chem Biol. 2002 Apr;9(4):455-63.
11. MacLeod DL, Nelson LE, Shawar RM, Lin BB, Lockwood LG, Dirk 
JE, et al. Aminoglycoside-resistance mechanisms for cystic fibrosis 
Pseudomonas aeruginosa isolates are unchanged by long-term, in-
termittent, inhaled tobramycin treatment. J Infect Dis. 2000 Mar; 
181(3):1180-4.
12. Jo JT, Brinkman FS, Hancock RE. Aminoglycoside efflux in Pseudo-
monas aeruginosa: involvement of novel outer membrane proteins. 
Antimicrob Agents Chemother. 2003 Mar;47(3):1101-11.
13. Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resis-
tance mechanism against aminoglycosides. Clin Infect Dis. 2007 Jul 
1;45(1):88-94.
14. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. 
Emerg Infect Dis. 2001 Mar-Apr;7(2):337-41.
15. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. 
Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-
oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents 
Chemother. 2000 Dec;44(12):3322-7.
16. Vahaboglu H, Hall LM, Mulazimoglu L, Dodanli S, Yildirim I, Liver-
more DM. Resistance to extended-spectrum cephalosporins, caused 
by PER-1 beta-lactamase, in Salmonella typhimurium from Istanbul, 
Turkey. J Med Microbiol. 1995 Oct;43(4):294-9.
17. Mugnier P, Dubrous P, Casin I, Arlet G, Collatz E. A TEM-derived 
extended-spectrum beta-lactamase in Pseudomonas aeruginosa. 
Antimicrob Agents Chemother. 1996 Nov;40(11):2488-93.
18. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem 
resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemoth-
er. 1991 Jan;35(1):147-51.
19. Lee K, Kim YA, Park YJ, Lee HS, Kim MY, Kim EC, et al. Increasing 
prevalence of vancomycin-resistant enterococci, and cefoxitin-, imi-
penem- and fluoroquinolone-resistant gram-negative bacilli: a KON-
SAR study in 2002. Yonsei Med J. 2004 Aug 31;45(4):598-608.
20. Lee H, Yong D, Lee K, Hong SG, Kim EC, Jeong SH, et al. Antimi-
crobial resistance of clinically important bacteria isolated from 12 
hospitals in Korea in 2004. Korean J Clin Microbiol. 2005 Apr;8(1): 
66-73.
21. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the 
management of multidrug-resistant gram-negative bacterial infec-
tions. Clin Infect Dis. 2005 May 1;40(9):1333-41.
22. Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou 
P, Michalopoulos A. Outcome of infections due to pandrug-resistant 
(PDR) Gram-negative bacteria. BMC Infect Dis. 2005 Apr 8;5:24.